Wellington Management Group LLP Acquires 5.2% Passive Stake in Stoke Therapeutics, Inc.

On May 15, 2026, Wellington Management Group LLP, along with its affiliated entities including Wellington Group Holdings LLP and Wellington Investment Advisors Holdings LLP, filed a Schedule 13G reporting a new 5.2% ownership stake in Stoke Therapeutics, Inc. (STOK). The group beneficially owns a total of 3,095,700 shares of Common Stock as of the event date on March 31, 2026. This filing marks an increase from a previous 0% ownership level, crossing the 5% threshold for passive institutional investors. The shares are held of record by various clients of the Wellington Investment Advisers, with Wellington Management Group LLP acting as the parent holding company. The filing specifies that the shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The reporting persons share dispositive power over the full 3,095,700 shares, while shared voting power is reported for 2,889,524 shares.